United Therapeutics Q2 2024 GAAP EPS $5.85 Misses $6.47 Estimate, Sales $714.900M Beat $691.867M Estimate
Portfolio Pulse from Benzinga Newsdesk
United Therapeutics reported Q2 2024 GAAP EPS of $5.85, missing the estimate of $6.47. However, sales were $714.9 million, beating the estimate of $691.867 million.
July 31, 2024 | 10:46 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
United Therapeutics' Q2 2024 earnings per share (EPS) missed estimates, but the company reported higher-than-expected sales.
The mixed results, with EPS missing but sales beating estimates, may lead to a neutral short-term impact on the stock price. Investors may weigh the earnings miss against the positive sales performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100